Australia markets closed

Poxel S.A. (PXXLF)

OTC Markets OTCPK - OTC Markets OTCPK Delayed price. Currency in USD
Add to watchlist
0.7000+0.1550 (+28.44%)
At close: 09:45AM EDT

Poxel S.A.

Immeuble Le Sunway
259-261 Avenue Jean JaurEs
Lyon 69007
France
33 1 44 71 94 94
https://www.poxelpharma.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees15

Key executives

NameTitlePayExercisedYear born
Mr. Thomas Kuhn M.B.A., Pharm D MBA, Pharm.D.Co-Founder, CEO & Director443.19kN/AN/A
Dr. Sébastien Bolze Ph.D., Pharm D Ph.D., Pharm.D.Co-Founder, COO and Executive VP of Project Management, Non Clinical & Manufacturing OperationsN/AN/AN/A
Dr. Pascale Fouqueray-Grellier M.D., Ph.D.Co-Founder and Executive VP of Clinical Development & Regulatory AffairsN/AN/AN/A
Dr. Sophie Hallakou-Bozec Ph.D.Co-Founder and Executive VP of R&D Pharmacology & Scientific CommunicationN/AN/AN/A
Arthur RouilleInvestor Relations OfficerN/AN/AN/A
Mr. Quentin DurandExecutive VP, Chief Legal Officer & Head of Corporate Social ResponsibilityN/AN/AN/A
Ms. Sylvie BertrandVice President of Human ResourcesN/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. The company's lead product is TWYMEEG (Imeglimin), an oral drug candidate that targets mitochondrial dysfunction and approved for the treatment of type 2 diabetes in Japan. It also develops PXL770, an adenosine monophosphate-activated protein kinase enzyme, which is in a Phase 2a clinical trial that treats chronic metabolic diseases, including diseases that affect the liver, such as non-alcoholic steatohepatitis (NASH); PXL065, an earlier stage programs that is in Phase 2 for the treatment of NASH focusing on chronic and rare metabolic indications. The company has a licensing agreement with Enyo Pharma S.A.S. for the development of farnesoid X receptor that is in Phase 2a study for the treatment of hepatitis B and NASH; and DeuteRx LLC for the development of PXL065, a mitochondrial dysfunction; and Sumitomo Pharma for development and commercialization of Imeglimin. Poxel S.A. was incorporated in 2009 and is headquartered in Lyon, France.

Corporate governance

Poxel S.A.’s ISS governance QualityScore as of 1 June 2024 is 10. The pillar scores are Audit: 5; Board: 9; Shareholder rights: 4; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.